KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Current Liabilities (2016 - 2025)

CRISPR Therapeutics AG's Total Current Liabilities history spans 11 years, with the latest figure at $149.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 69.88% year-over-year to $149.1 million; the TTM value through Dec 2025 reached $149.1 million, up 69.88%, while the annual FY2025 figure was $149.1 million, 69.88% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $149.1 million at CRISPR Therapeutics AG, up from $119.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $150.9 million in Q3 2022 and bottomed at $83.1 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $119.0 million (2024), against an average of $116.0 million.
  • The largest annual shift saw Total Current Liabilities dropped 26.27% in 2023 before it surged 69.88% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $119.9 million in 2021, then rose by 1.02% to $121.1 million in 2022, then decreased by 10.17% to $108.8 million in 2023, then decreased by 19.31% to $87.8 million in 2024, then soared by 69.88% to $149.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Total Current Liabilities are $149.1 million (Q4 2025), $119.0 million (Q3 2025), and $104.4 million (Q2 2025).